ISSN:
1432-1238
Keywords:
Ganciclovir
;
Hemodialysis
;
Pharmacokinetics
;
CVVHD
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
Abstract Objective Data is scarce concerning ganciclovir, used in CMV-related diseases in transplant patient with renal failure, especially when dialysis is necessary. Design Prospective trial. Setting Intensive care unit in a university hospital, and pharmacy laboratory. Patients Pharmacokinetics were obtained in 3 patients undergoing continuous veno-venous hemodialysis (CVVHD) (PAN 69). Interventions HPLC measurements of plasmatic and ultrafiltrated ganciclovir were determined at 17 times intervals after a 5 mg/kg every 48 h dosage. Results Peak and trough concentrations were respectively 16.1±2.4 and 5.5±0.5 mg/l, sieving coefficient 0.75–0.95, and volume of distribution at steady state 0.64±0.09 l/kg, half life (beta phase) 18.6±1.8 h. No direct toxicity, or CMV-related death occurred. Conclusion Plasma concentrations were higher than the ID 90. A dosage of 5 mg/kg/48 h of ganciclovir could be used during CVVHD, and ideally adjusted to monitoring of plasma drug levels.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/BF02425056
Permalink
